Company: DHR
Filing Date: 2025-07-22
Form Type: 10-Q
Source: 0000313616-25-000153
Chunk: 41

Company: DANAHER CORP /DE/
Filing Date: 2025-07-22
Form: 10-Q
Item: Item 1
Chunk 41
---
 segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines.  The Company’s solutions support a broad range of biotherapeutics including monoclonal antibodies, recombinant proteins, replacement therapies such as insulin and vaccines, as well as novel cell, gene, mRNA and other nucleic acid therapies.

28

Biotechnology Selected Financial Data 

 Three-Month Period EndedSix-Month Period Ended($ in millions)June 27, 2025June 28, 2024June 27, 2025June 28, 2024Sales$1,850 $1,713 $3,462 $3,237 Operating profit531 462 972 787 Depreciation38 35 72 77 Amortization of intangible assets228 214 441 432 Operating profit as a % of sales28.7 %27.0 %28.1 %24.3 %Depreciation as a % of sales2.1 %2.0 %2.1 %2.4 %Amortization as a % of sales12.3 %12.5 %12.7 %13.3 %

Sales Growth and Core Sales Growth% Change Three-Month Period Ended June 27, 2025 vs. Comparable 2024 Period% Change Six-Month Period Ended June 27, 2025 vs. Comparable 2024 PeriodTotal sales growth (GAAP)8.0 %7.0 %Impact of:Currency exchange rates (2.0)%(0.5)%Core sales growth (non-GAAP)6.0 %6.5 %

Price increases in the segment contributed 2.5% and 2.0%, respectively, to sales growth on a year-over-year basis during the three and six-month periods ended June 27, 2025 and are reflected as a component of core sales above.

Total segment sales increased 8.0% and 7.0% during the three and six-month periods, respectively.  The increase in segment sales in the three and six-month periods was led by increased core sales and to a lesser extent by the impact of currency exchange rates.  The year-over-year increase in total segment core sales was led by increased sales of